Effect of SophorOx® on Oxidative Stress and Body Composition in Individuals with High BMI: A Randomized Controlled Trial
The study aimed to investigate the efficacy and safety of SophorOx® (LN-OS-22) on oxidative stress and body composition in adults with excessive body weight and obesity. The 56-days randomized, double-blind, placebo-controlled, parallel-group, multi-centric clinical trial had individuals aged 30–60 years with body mass index (BMI) ≥25 to ≤34.9 kg/m2. 68 participants were randomly allocated to LN-OS-22 or placebo groups. As compared to placebo, at the end of study, statistically significant reductions were demonstrated in body weight, waist circumference and BMI in the LN-OS-22 group (p < 0.0001). The study demonstrates that LN-OS-22 was effective in reducing the oxidative stress, anthropometrics and improving the quality of life in individuals with overweight and obesity.
